Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu

Trombositler birçok kardiyovasküler olayda merkezi role sahiptirler. Tirofiban, trombosit agregasyonunu önleyen bir glikoprotein (GP) IIb/IIIa reseptör inhibitörüdür. Bu olguda tirofiban tedavisi sonrası gelişen trombositopeni ve trombositopeni yapan diğer nedenlerin gözden geçirilmesi amaçlandı. Anahtar kelimeler: Tirofiban, Trombositopeni, GP IIb/IIIa İnhibitörleri

Abstract

Platelets have a central role in many cardiovascular events. Tirofiban is a glycoprotein (GP) IIb/IIIa receptor inhibitor that prevents platelet aggregation. In this report, it was aimed to review the thrombocytopenia induced by tirofiban treatment and other causes of thrombocytopenia. Key words: Tirofiban, Thrombocytopenia, GP IIb/IIIa İnhibitors

Anahtar kelimeler

Tirofiban Trombositopeni GP IIb/IIIa İnhibitörleri Thrombocytopenia GP IIb/IIIa İnhibitors

🔖

Bu Makaleye Atıf Yap

Açıkgöz, N., Ermiş, N., Cansel, M., Yağmur, J., Pekdemir, H., Özdemir, R. (2010). Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu. Turgut Özal Tıp Merkezi Dergisi, Cilt: 17 Sayı: 1, 55–57. https://ajindex.com/articles/1433926

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

Boersma E, Harrington EA, Moliterno DJ, White H, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a metaanalysis of all major randomised clinical trials. Lancet 2002;359(9302):189-98.
Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32.
Özmen F, Atalar E, Özer N. Akut koroner sendromda trombositler ve glikoprotein IIb/IIIa inhibitörleri. Türk J Cardiol 2007;10:91-100.
Abrams CS, Cines DB. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors. Curr Hematol Rep 2004;3:143-47.
Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 1999;362-66.
Holmes MB, Kabbani S, Watkins M, Battle RW, Schneider DJ. Abciximab associated pseudothrombocytopenia. Circulation 2000;101:938–39.
Warkentin TE, Aird WC, Rand JH. Platelet-endothelial intereactions: sepsis, HIT and antiphospholipid syndrome. Hematology 2003;497-519.
Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH. Acute thrombocytopenia after treatment with tirofiban or eptifibatide Thrombocytopenia after tirofiban is associated with antibodies specific for ligand- occupied GPIIb/IIIa. Blood 2002;100:2071-6.
Curtis B, Swyers J, Divgi A, McFarland J, Aster R. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab coated platelets. Blood 2002;99:2054-9.
Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu
Eryonucu B, Tuncer M, Erkoc R. Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. Cardiovasc Drugs Therapy 2004;18:503-5.
Demirkan B, Guray Y, Guray U, Korkmaz S. Differential diagnosis and management of acute profound thrombocytopenia by tirofiban: a case report. J Thromb Thrombolysis 2006;22:77-8.
Beiras-Fernandez A, Kowert A, Jiru P, Weis M, Spannagl M, Reichart B, Schmoeckel M. Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting. Ann Thorac Surg 2009;87(2):629-31.